Satellos Bioscience Inc.
MSCLF$188M
Micro CapNASDAQBiotechnology🇺🇸North America14 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 31, 2026
7wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
SAT-3247 Phase 2 Results Expected
Mar 31, 2026SAT-3247
Primary completion for SAT-3247 trial (NCT07287189) in Duchenne Muscular Dystrophy
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
MSCLF News